TP53 and endometrial cancer: However, prospective studies, such as PORTEC-4a (Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer; NCT03469674) and TAPER (Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype Early Stage Endometrial Cancer; NCT04705649), are currently on-going, from which additional results are expected (9,10).